Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 30, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - September 30, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/30/14 - Acasti Announces Positive Top-Line Pharmacokinetic Results
Acasti Pharma Inc., an emerging biopharmaceutical company, announces top-line results for its pharmacokinetic trial evaluating the bioavailability and safety of CaPre on healthy individuals taking single and multiple daily oral doses of the Corporation's new investigational drug candidate composed of a patent-protected highly concentrated...
9/30/14 - ADC Therapeutics Expands Team
Dr Mulkerrin has more than 20 years of industry experience in biologics manufacturing, most recently as Vice President, Process Development and Manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech. Dr Simon Chivers joins as Head of Toxicology. Dr. Chivers has more than 15 years of industry experience, most recentl
9/30/14 - Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology
In the interview posted online since September 15, Pharma IQ asked Dr. Sherley to respond to several questions on the current state of technologies for evaluating stem cell toxicity, challenges to evaluating stem cell toxicity, and future trends in the use of stem cells for toxicological drug evaluations. Dr. Sherley was invited to lead the session
9/30/14 - Aerie Announces Closing of $125 Million Convertible Notes Financing
BEDMINSTER, N.J.& RESEARCH TRIANGLE PARK, N.C.& NEWPORT BEACH, Calif. Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, announced today that it has closed its $125 million financing with Deerfield Management Company L.P., a curre
9/30/14 - Akorn Acquires Xopenex(R) (levalbuterol HCI) Inhalation Solution From Sunovion
Akorn, Inc., a niche pharmaceutical company, today announced that it has signed a definitive agreement to acquire certain rights to short-acting bronchodilator Xopenex Inhalation Solution from Sunovion Pharmaceuticals Inc. for $45 million, paid in cash at closing, net of certain liabilities. "We are excited to announce this transaction which
9/30/14 - Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it has received a $25 million advance from Hercules Technology Growth Capital, Inc.. The payment is the second and final advance under the Loan and Security Agreement
9/30/14 - Alios BioPharma Announces Acquisition Agreement With Johnson & Johnson
"We are so pleased to be joining the Janssen Pharmaceutical Companies of Johnson& Johnson, who have an impressive track record of bringing breakthrough drugs for viral diseases to market," said Lawrence M. Blatt, PhD, President and Chief Executive Officer of Alios BioPharma. Goldman, Sachs& Co. acted as exclusive financial advisor to Alios BioPharm
9/30/14 - Amicus Therapeutics to Present at Leerink Partners Rare Disease Roundtable
Amicus Therapeutics today announced that Bradley Campbell, Chief Operating Officer and Chip Baird, Chief Financial Officer, will present a corporate overview at the Leerink Partners Rare Disease Roundtable in New York, NY on Wednesday, October 1, 2014 at 8:50 a.m. ET. A live webcast of the presentation can be accessed through the Investors sectio
9/30/14 - Announce Ebola Cure and Go to Jail, FDA Warns
The very act of suggesting or announcing a potential cure for the dreaded Ebola Virus Disease, EVD, has become riskier than envisaged as claimants of such unverified and "unorthodox" cures now stand the risk of going to prison if threats by the American Food and Drug Administration, FDA, are anything to go by. Just last week, the American Food and
9/30/14 - Asterias Biotherapeutics Signs Pact with Cancer Research UK and Cancer Research Technology [Professional Services Close - Up]
BioTime reported that its subsidiary Asterias Biotherapeutics has reached an agreement with Cancer Research UK and Cancer Research Technology, the charity's development and commercialization arm, to conduct a clinical trial of Asterias' novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer. We are delighted to partner..
9/30/14 - Avedro Announces Resubmission of New Drug Application to FDA for Corneal Cross-Linking
Avedro Inc., a Boston- based ophthalmic medical device and pharmaceutical company announces today that it resubmitted its New Drug Application for riboflavin ophthalmic solution/ KXL System to the U.S. The proposed indications of treatment of progressive keratoconus or corneal ectasia following refractive surgery were both granted orphan status
9/30/14 - Baxter to Form New Global Innovation and R%7ED Center Near Boston for Its BioPharmaceuticals Business [Global Data Point]
The R %7 ED positions that will relocate to the new center are currently based in California and Europe. Joining this unmatched biotech community is an important step, "said Ludwig Hantson, Ph.D., president of Baxter BioScience.&# x0D;. "Our new innovation center will increase R %7 ED collaboration and efficiency, connect us directly to a rich poo
9/30/14 - BBK Worldwide's Mobile App Secures Spot as a Finalist for the 2014 SCRIP Awards [Professional Services Close - Up]
BBK Worldwide said that its mobile app for patient and site engagement, My Clinical Study Buddy, is a finalist for a 2014 SCRIP Award, "Best Technological Development in Clinical Trials" category. Selected by a panel of esteemed judges, award winners will be announced at a ceremony in London on December 3. According to a company release, launched a
9/30/14 - Brainsway Deep TMS Brings Substantial Improvement to OCD Patients in Deep TMS Study
Brainsway Ltd. is pleased to report substantial improvement in OCD patients following Brainsway Deep TMS treatment in a clinical study held in Sheba Medical center, Tel Ha'Shomer, Israel. Joseph Zohar, who was the chairperson of the anxiety and OCD section of the World Psychiatric Association, included 41 OCD patients who did not respond adequate
9/30/14 - Celgene Secures FDA Approval for Oral OTEZLA (apremilast) for Treatment of Patients with Moderate to Severe Plaque Psoriasis [Professional Services Close - Up]
Celgene said that the U.S. Food and Drug Administration has approved OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4, for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. "OTEZLA offers a valuable treatment option for a spectrum of plaque psoriasis p
9/30/14 - Celldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology
Celldex Therapeutics, Inc. announced today the publication of two papers highlighting early studies of glembatumumab vedotin in breast cancer and metastatic melanoma in the Journal of Clinical Oncology. The papers, " A Phase 1/ 2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma" and " A Phase 1/ 2 Stud
9/30/14 - CereSpir Incorporated Appoints Adrian N. Hobden, Ph.D., as Chairman of Its Board of Directors
CSP-1103 has undergone Phase 2 testing in people with Mild Cognitive Impairment, and CereSpir is integrating the findings to finalize the Phase 3 clinical protocol in consultation with key opinion leaders in AD research and the U.S. Food and Drug Administration. He retired from Myrexis in 2011. Hobden earned his Bachelor's and Master's degrees in..
9/30/14 - CIS Acquisition Reports on Execution of Pact with Delta Technology Holdings Limited [Manufacturing Close - Up]
CIS Acquisition recently reported the execution of a definitive agreement with Delta Technology Holdings Limited, a China based company specializing in providing fine and specialty chemicals to end application markets including Automotive, Pharmaceutical, Agrochemical, Dye& Pigments, Aerospace, Ceramics, Coating-Printing and Food Additives by...
9/30/14 - Clinical Findings Published in The Lancet Support Administration of Flu Vaccine with PharmaJet's Needle-Free Injector
A clinical study published in the August 23, 2014 issue of The Lancet demonstrated that delivery of AFLURIA with the PharmaJet Needle-Free Injector compared favorably to traditional needle and syringe delivery. In the PharmaJet study, 89 percent of the people receiving the PharmaJet Needle-Free Injection reported they would choose to receive thi
9/30/14 - Collegium Pharmaceutical Assigned Patent
ALEXANDRIA, Va., Sept. 30 Collegium Pharmaceutical, Canton, Massachusetts, has been assigned a patent developed by five co-inventors for "amper-resistant pharmaceutical compositions of opioids and other drugs." The co-inventors are Said Saim, New Milford, Connecticut, Alison B. Fleming, North Attleboro, Massachusetts, Jane C. Hirsh, Wellesley, Ma
9/30/14 - Critical Outcome Technologies First Quarter Marked by Key Developments for COTI-2 [Global Data Point]
?receiving the Orphan Drug Designation from the U.S. Food and Drug Administration for COTI-2 in the treatment of ovarian cancer;&# x0D;. ?commencing trading on the OTCQB venture stage marketplace in the United States under the symbol COTQF.&# x0D;. Wayne Danter, President and CEO.
9/30/14 - CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs
CSL Behring announced that it is set to commence operations in its newly expanded facility now that the U.S. Food& Drug Administration has granted approval. The new facility will use the same state-of-the-art technology as CSL Behring's long-standing manufacturing center of excellence in Bern, Switzerland. CSL Behring's Executive Vice President G
9/30/14 - CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2 b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer who have relapsed or were refractory to prior chemotherapy.
9/30/14 - DanDrit Biotech A/S Signs Agreement to Commence Clinical Trials of MelCancerVac
DanDrit Biotech A/S, the subsidiary of DanDrit Biotech USA, Inc., a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino"- IST National Institute for Cancer Research known as the San Martino Hospital of Genoa.
9/30/14 - Diamond BioPharm Ltd Open a New UK Satellite Office at the Cambridge Science Park
Diamond BioPharm Ltd announce today the opening of a new satellite office at Cambridge Science Park. "We are delighted to be expanding into our new satellite office in Cambridge," said Dr Maureen Graham, Managing Director of Diamond BioPharm Ltd. "This move will allow us to continue to deliver an outstanding consulting service to our clients throu
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


The Diversion of Controlled Substances and the Law
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement